Recent evidence has demonstrated L1CAM as an oncogenic driver in various malignancies,23–27 and the clinical burden and prognostic biomarker potential of L1CAM expression evaluated by immunohistochemistry has been shown in several cancers, including GC. The gene discussed is L1CAM; the disease is cancer.